News
Survival of patients with mCRPC on hormone therapy differs by race
SAN FRANCISCO – An analysis of male veterans finds that African American men with chemotherapy-naive mCRPC treated with abiraterone or...
News
Pembrolizumab-axitinib nearly halves risk of death in RCC
SAN FRANCISCO – Pembrolizumab and axitinib combination therapy netted superior progression-free and overall survival relative to sunitinib in...
News
Radioligand is highly active in metastatic castrate-resistant prostate cancer
SAN FRANCISCO – Lutetium-177 PSMA-617 (LuPSMA) netted a high rate of PSA response and impressive overall survival among patients who had run out...
News
Pancreatic cancer expression signature is linked to chemoresistance
SAN FRANCISCO – Whole-genome and RNA sequencing of pancreatic cancers in the COMPASS trial has tied an RNA expression signature to poorer survival...
News
Gastrectomy does not alter benefit of new oral chemo in gastric cancer
SAN FRANCISCO – In the phase 3 TAGS trial, the gastrectomy subgroup did have higher rates of grade 3 or 4 adverse events.
News
Cancer vaccine fails in CRC but trial yields lessons
SAN FRANCISCO – Tecemotide did not improve recurrence-free or overall survival relative to placebo when given after R0/R1 resection of liver-only...
News
Dual BRAF, MEK inhibition proves highly active in biliary tract cancer
SAN FRANCISCO – Patients with BRAF V600E–mutated biliary tract cancer in a basket trial had a response rate of 42% when given the combination of...
News
mRECIST response to kinase inhibitors predicts survival in HCC
SAN FRANCISCO – Among patients with untreated HCC given first-line kinase inhibitors, those having a response based on mRECIST criteria lived...
News
Pembrolizumab bests chemo in PD-L1-positive esophageal cancer
SAN FRANCISCO – In KEYNOTE-181, second-line pembrolizumab reduced risk of death by 31% relative to chemotherapy among patients whose esophageal...
News
Age may dictate benefit of andecaliximab in gastric cancer
SAN FRANCISCO – Older adults appeared to derive both progression-free and overall survival benefit in the GAMMA-1 trial, which tested addition of...
News
COLOPEC: Adjuvant HIPEC for high-risk colon cancer disappoints
SAN FRANCISCO – Adding adjuvant oxaliplatin HIPEC to routine adjuvant systemic chemotherapy did not improve survival without peritoneal recurrence...
News
Young women opt for mastectomy even when neoadjuvant chemo works well
SAN ANTONIO – Although neoadjuvant chemotherapy doubled the proportion of women eligible for breast-conserving surgery, about 40% chose mastectomy...
News
Older breast cancer patients given adjuvant chemo live longer
SAN ANTONIO – Overall survival is better in breast cancer patients aged 65 years and older who receive adjuvant chemotherapy, although patients...
News
QOL is poorer for young women after mastectomy than BCS
SAN ANTONIO – A cohort study of 560 breast cancer survivors aged 40 or younger at diagnosis finds that breast satisfaction and several domains of...
News
Oxybutynin rapidly quells hot flashes
SAN ANTONIO - Oxybutynin reduced hot flash scores by at least two-thirds, improved measures of quality of life, and was safe and well tolerated in...